Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944046 | 0.82 | NFKB1 (0.57) | RAB9ANPC1TP53SMN1; SMN2PKM | |
| SCHEMBL7576844 | 0.77 | ALDH1A1 (0.56) | RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL7997523 | 0.76 | NPC1 (0.43) | RAB9ANPC1SMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL1639175 | 0.76 | NPC1 (0.43) | RAB9ANPC1TP53SMN1; SMN2NFKB1 | |
| SCHEMBL3809482 | 0.75 | KMT2A (0.45) | RAB9ANPC1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL2951566 | 0.73 | ALOX5 (0.41) | RAB9AMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL4855606 | 0.73 | ALDH1A1 (0.38) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL3812073 | 0.71 | MEN1 (0.35) | RAB9ASMN1; SMN2ALDH1A1MAOBMEN1 | |
| SCHEMBL3811529 | 0.71 | GAA (0.38) | RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL31038829 | 0.71 | ALDH1A1 (0.53) | RAB9ANPC1TP53SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754754-B2 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2010-07-13 | — | — | US | claimed |
| EP-1596852-B1 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-05-27 | — | — | EP | claimed |
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2006-02-02 | — | — | US | claimed |
| EP-1596852-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| WO-2004071380-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2004-08-26 | — | — | WO | claimed |
| US-7754754-B2 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| EP-1596852-B1 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| EP-1596852-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004071380-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | AADAT, DDC, AADAC | RAB9A 933/4885NPC1 448/4885TP53 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.